Previous 10 | Next 10 |
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
2023-12-02 02:24:45 ET Summary AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to revitalize its struggling oncology operations. ImmunoGen's recent success with its drug ELAHERE, which received accelerated approval for the treatment of ovarian cance...
2023-12-01 14:45:02 ET Summary AbbVie Inc. is acquiring ImmunoGen, Inc. at a 94.6% premium, with shares now trading at a 6.6% upside to the deal's successful closing. The likelihood of an overbid is low due to a high termination fee and the current state of the biotech industry. ...
NEW YORK, NY / ACCESSWIRE / December 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Rover Group, Inc. (NASDAQ:RO...
NEW YORK, NY / ACCESSWIRE / December 1, 2023 / Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and h...
2023-12-01 08:52:41 ET More on AbbVie, ImmunoGen, etc. AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology AbbVie's $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained AbbVie: Get Ready For More Painful Downside AbbVie-ImmunoGen ...
2023-11-30 19:19:34 ET The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV) , enjoyed a nearly 3% lift after the news was announced, contrasting quite favorabl...
2023-11-30 16:03:03 ET Summary AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian cancer treatment, and enhancing its oncology portfolio. ImmunoGen's advanced ADC pipeline, including potential blockbusters, complements AbbVie's existing prog...
2023-11-30 15:10:23 ET Summary AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline and potentially transforming its cancer care business. ImmunoGen's antibody drug conjugate, Elahere, is approved to treat ovarian cance...
2023-11-30 14:54:50 ET Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share of Im...
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...